EL.En. Sells the Commodity, Keeps the Margin
The reshaped company
On 5 November EL.En. closed the sale of 80% of its laser-cutting business to TRUMPF, finishing a retreat that began a year earlier with the disposal of Penta Laser Zhejiang. The nine-month numbers already show the shape the company now claims to be: revenue of EUR 363 million, up 7.6%, with the medical segment at EUR 335 million (+8.9%) — roughly 92% of the whole — and the residual industrial rump at EUR 28 million, down 6.4%. “These are excellent results, and they come in a year in which EL.En. has also changed shape, becoming more focused, more profitable and better positioned for the future.” — Andrea Cangioli, CEO · 2026-11-16
The logic offered for selling Cutlite Penta is unusually candid and worth holding onto: in laser cutting, the laser source has become a commodity bought from third parties, so the group's core skill — designing and controlling the light source at the heart of the machine — stopped being the differentiator. What remains in industry is exactly what EL.En. still makes itself: marking, medium-power CO2 laser sources, and cultural-heritage restoration. This is a portfolio decision dressed as a technology decision, and it happens to be the right one for the margin story.
The margin is the message
Gross margin went from 48.5% to 50.5%. EBITDA rose 29% to EUR 76.2 million, a 21% margin. EBIT rose 32.6% to EUR 67.9 million, taking the operating margin from 15.2% to 18.7%, with the third quarter alone printing a 21% EBIT margin against 17.6% a year earlier. Management names three engines: a favourable product mix led by anti-aging technologies, a deliberate program to cut the cost of goods sold across DEKA, Quanta and Asclepion, and plain operating leverage. A fourth, less advertised, is structural: the new distribution hub for urology in the United States pulled a distributor's margin in-house, generating EUR 12 million of revenue in seven months.
The obvious question — is ~20% sustainable — got a textbook hedge rather than a promise. “We hope and we work in order to be able to keep EBIT margin so high” — Andrea Cangioli, CEO · 2026-11-16, the CEO said, before listing mix, cost work and quarterly volume, and then warning that copycats and large competitors are everywhere. Note also a piece of accounting fog that is about to lift: IFRS 5 stripped roughly EUR 2.3 million out of reported EBIT and pushed it below the line, so the underlying nine-month figure is nearer EUR 70 million. The keyword trail confirms the fog is dissipating — income statement now registers as one of the company's sharpest keyword decliners after quarters of heavy use, simply because the deal is done and there is nothing left to reclassify.
What got louder, and what went quiet
The genuinely new caution in this call is Germany. The DACH region, via Asclepion's direct network, has been described on prior calls as a growth engine; this quarter it is the soft spot:
That matters because it undermines the "geographic balance" defence at exactly the moment the group leans hardest on medical. Meanwhile the Gulf area weakness is now a three-call-old refrain — the CFO reported non-European medical growth of 16.3% while Italy fell 8% and Europe was flat — and management is answering with marketing events in Egypt rather than with a forecast of recovery. Interesting divergence: the global keyword set spent 2026Q1 and 2026Q2 consumed with Middle East conflict and Iran war themes; by this quarter the market has moved on to tariffs, Fed policy and AI agents, while EL.En. is still absorbing the commercial aftermath.We see signs of slowdown on the German market. This is evident in the industrial field, but it's evident also in the medical side.
Then there is MonaLisa Touch, which ranks among the company's highest-momentum keywords this quarter precisely because the CEO spent a paragraph explaining why he is not investing in it. Analysts have now asked about it twice — September 2025 and September 2026 — and both times the answer was the same: “we don't believe that today, a very large investment to return on exactly this technology in the United States ... is worth.” — Andrea Cangioli, Chief Executive Officer (CEO) · 2026-09-11 This quarter was blunter still: “But specifically for MonaLisa Touch, we do not have a program.” — Andrea Cangioli, CEO · 2026-11-16 A high-ranking keyword built on a disavowal is a useful signal in itself — the extractor hears emphasis, the reader should hear a decision not to spend.
The other long-running sore is hair removal, weak since at least 2025, partly self-inflicted through the Cynosure/Lutronic merger that removed a customer. The CEO now concedes he cannot tell whether EL.En.'s own devices are being beaten on performance or cost, or whether distributors are simply absorbing the attention that Onda and RedTouch soak up: “I believe hair removal will be an area of deeper investigation for us in the near future.” — Andrea Cangioli, CEO · 2026-11-16 After several quarters of blaming the market, admitting the product question is a small but real shift.
Cash, chairs and conservatism
Net financial position stood at EUR 192.5 million at September, up from EUR 172 million, with roughly EUR 30 million of TRUMPF proceeds still to land. Capex was only EUR 10.5 million while net working capital absorbed EUR 28 million — an old complaint here, and management's answer has not changed. Nor has the answer on terms of M&A: small, capability-adjacent, nothing transformational, unchanged from September. “There is nothing new about any possible transformational M&A transaction.” — Andrea Cangioli, Chief Executive Officer (CEO) · 2026-09-11 With the balance sheet this full and the share count static, the absence of an extraordinary-dividend conversation is itself notable — the CEO explicitly ruled one out while insisting the cash is not being hoarded against a downturn.
On guidance, the EUR 90 million EBIT target for the full year was described by the CEO as deliberately cautious, with an expectation that a strong fourth quarter would push the figure above that threshold rather than below it. An analyst read the same math and called it conservative; he was not argued with. The December quarter is the group's habitual record-setter, and management's refusal to bank on it is a timing comment, not a demand comment — the CEO even noted the irony that a strong fourth quarter mechanically weakens the first, and that the exceptional result in December needs several conditions to line up at once.
One governance thread quietly closed: after Paolo Salvadeo's departure, the General Manager role — the company's single highest-ranked keyword back in 2026Q1 — has been abolished rather than filled, with four functional heads now reporting to the executive directors. It now appears among the quarter's biggest keyword decliners, which is exactly what an org chart change should look like in data.
Why it matters
There is no market wave behind this. The global keyword board this quarter is tariffs, Fed hikes, AI agents, Grok, data centres and assorted policy noise; nothing there is EL.En.'s story. What we have is a company-unique self-help arc: the exit from a commoditised business, a two-point gross-margin gain, a four-point EBIT margin gain, and a management team telling you the number is achievable without an exceptional December. The risks are equally company-specific — a weakening German market, a hair-removal line under real competitive pressure, copies of its microwave technology proliferating in Asia, and a cash pile that keeps being described as earmarked for small things. The bet is that a leaner perimeter plus recurring fibers revenue and a direct US urology channel compounds faster than the legacy industrial drag decays. The evidence for that is stronger than it has been; the evidence against it — Germany, hair removal, and a distributor-heavy mix — has not gone away, it has just become the whole company's problem instead of a division's.